Related Experiment Video
Updated: Apr 27, 2026

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
Published on: January 28, 2021
Lipoprotein (a): gene genie
Paul N Durrington1, Jonathan D Schofield, Tarza Siahmansur
1aCardiovascular Research Group, School of Biomedicine, University of Manchester bCardiovascular Trials Unit, University Department of Medicine, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Insights
Lipoprotein (a) [Lp(a)] is a key genetic risk for cardiovascular disease (CVD). Despite extensive knowledge, clinical application and Lp(a)-lowering therapies face challenges due to measurement and role disagreements.
Area of Science:
- Biochemistry
- Genetics
- Cardiology
Background:
- Lipoprotein (a) [Lp(a)] is the most prevalent genetic risk marker for atherosclerotic cardiovascular disease (CVD).
- Despite its significance, clinical integration and targeted therapies remain limited.
- Understanding Lp(a) metabolism and its role in atherosclerosis is crucial.
Purpose of the Study:
- Review barriers hindering clinical progress for Lp(a).
- Discuss controversies impacting future research and therapeutic development.
- Highlight the need for standardized Lp(a) measurement and clinical assays.
Main Methods:
- Review of epidemiological and genetic studies on Lp(a).
- Analysis of Lp(a) metabolism and its relation to CVD risk.
- Evaluation of evidence for Lp(a)-lowering therapies and apheresis.
Main Results:
- Epidemiological and genetic data confirm a causal role for Lp(a) in atherosclerosis.
- Lp(a) levels, not isoform size, correlate more strongly with CVD risk.
- Selective Lp(a) apheresis shows potential for improving cardiovascular outcomes.
Conclusions:
- Significant knowledge exists on Lp(a), but clinical CVD reduction is lacking.
- Disagreements on measurement, physiological role, and Lp(a) elevations in specific conditions impede progress.
- Standardized assays and Lp(a)-lowering therapies are essential for clinical practice.
Purpose Of Review:
Despite being both the longest known and the most prevalent genetic risk marker for atherosclerotic cardiovascular disease (CVD), little progress has been made in agreeing a role for lipoprotein (a) [Lp(a)] in clinical practice and developing therapies with specific Lp(a)-lowering activity. We review barriers to progress, and discuss areas of controversy which are important to future research.
Recent Findings:
Epidemiological and genetic studies have supported a causal role for Lp(a) in accelerated atherosclerosis, independent of other risk factors. Progress continues to be made in the understanding of Lp(a) metabolism, and Lp(a) levels, rather than apolipoprotein (a) isoform size, have been shown to be more closely related to CVD risk. Selective Lp(a) apheresis has offered some evidence that Lp(a)-lowering can improve cardiovascular end-points.
Summary:
We have acquired a great deal of knowledge about Lp(a), but this has not yet led to reductions in CVD. This is at least partially due to disagreement over Lp(a) measurement methodologies, its physiological role and the importance of the elevations seen in renal diseases, diabetes mellitus and familial hypercholesterolaemia. Renewed focus is required to bring assays into clinical practice to accompany new classes of therapeutic agents with Lp(a)-lowering effects.
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
11:13Enrichment of Native Lipoprotein Particles with microRNA and Subsequent Determination of Their Absolute/Relative microRNA Content and Their Cellular Transfer Rate
Published on: May 9, 2019
Related Concept Videos
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacogenomics: Identification of New Drug Targets
Regulation of Nuclear Protein Sorting
Cell Specific Gene Expression
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...